secwatch.observer — SEC 8-K summary
======================================

Issuer:     TELA Bio, Inc. (TELA)
CIK:        0001561921
Form:       8-K
Filed at:   2026-05-12T20:11:00+00:00
Accession:  0001104659-26-059393
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

TELA Bio Q1 revenue $19.1M (+3% YoY); net loss $12.3M; reiterates FY2026 revenue growth at least 8%
--------------------------------------------------------------------------------

- Revenue $19.1M (+3% YoY), unit growth 13%; European revenue up 41% YoY.
- Net loss $12.3M vs $11.3M prior year; operating loss $10.5M.
- Gross margin 65.7% (down from 67.6%) on higher excess/obsolete inventory charge.
- Reiterated FY2026 revenue growth at least 8% over FY2025; Q2 2026 expected ~$20.0M.
- U.S. commercial launch of OviTex LTR (April 1) and board refreshment effective June 9, 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1561921/000110465926059393/0001104659-26-059393-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1561921/000110465926059393/tm2614218d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-059393

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer